Dyadic International Inc (DYAI)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Form 8-K - Current report

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic...

Form 8-K - Current report

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or...

Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a...

Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

JUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress

Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat...

Form DEF 14A - Other definitive proxy statements

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form PRE 14A - Other preliminary proxy statements